A B S T R A C T Plasma lipoproteins from patients with familial lecithin: cholesterol acyltransferase (LCAT) deficiency have been fractionated by preparative ultracentrifugation and gel filtration and their lipid content and reactivity studied. All of the lipoproteins are abnormal with respect to lipid concentration or relative lipid content. The low density lipoproteins (LDL) and high density lipoproteins (HDL) appear to react normally with partially purified LCAT from normal plasma. Also, the lipids of the very low density lipoproteins (VLDL) and LDL, like those of the corresponding lipoproteins of normal plasma, are indirectly altered by the action of LCAT on normal HDL. Thus, during incubation in vitro VLDL cholesteryl ester is increased and VLDL triglyceride is decreased, as described by others for VLDL from hyperlipemic plasma, and both the unesterified cholesterol and lecithin of the VLDL and LDL are decreased. The patients' VLDL and LDL are abnormal, however, in that they lose unesterified cholesterol and lecithin to normal HDL in the absence of LCAT. Also, the patients' HDL lose these lipids to erythrocyte membranes in the absence of the enzyme.
INTRODUCTION
An inborn error of metabolism, which may yield important new information about plasma lipoprotein physiology, was recently discovered in Scandinavia (1) (2) (3) . This disease is characterized by corneal infiltration, anemia, and proteinuria, by several plasma lipoprotein abnormalities, and by absence or near absence of plasma lecithin: cholesterol acyltransferase (LCAT) activity. The disease has been provisionally named familial LCAT deficiency (1) because the lipid abnormalities that seem to be most significant, viz., the unusually low levels of cholesteryl ester and lysolecithin in plasma (1, 3) and the unusually high levels of unesterified cholesterol and lecithin in plasma and erythrocytes (1, 3, 4) , appear to be caused by the enzyme deficiency. Nevertheless, many features of the disease remain to be explained or even described at the molecular level. Consequently, inability to synthesize or secrete LCAT is not conclusively established as.the primary defect.
One particularly critical question is whether all the plasma lipoprotein abnormalities are directly or indirectly caused by the enzyme deficiency. The possibility has not been ruled out that some primary lipoprotein abnormality underlies the LCAT deficiency. Before this question can be resolved, the lipoprotein abnormalities themselves will have to be carefully defined; not only the lipid composition and reactivity, but also the peptide composition and overall structure of the individual lipoproteins will have to be considered. With this objective in mind we initiated the present investigation of the lipid composition and reactivity toward LCAT of the patient's very low, low, and high density lipoproThe Journal of Clinical Investigation Volume 49 1970 teins (VLDL, LDL, HDL). We also reasoned that, irrespective of the identity of the primary defect, a study of the abnormalities most directly related to the LCAT deficiency might provide significant information about the normal effects of the LCAT reaction on the composition and structure of plasma lipoproteins.
METHODS
Patients. The three patients studied are females. Two, M. R. (age 21) and A. R. (age 35), were described in the original reports of the disease (1, 2) . The third, A. A. (age 42) from a second Norwegian family, was described more recently (5) . Except in one series of experiments in which A. R. had been on a high carbohydrate, low fat diet during the week before her blood was withdrawn, the patients were under no special form of treatment.
Plasma was prepared from the blood of the patients and the normal controls after they had fasted overnight. 0.005 M EDTA or acid citrate dextrose solution (U.S.P. Formula A) was used as anticoagulant. Sodium p-chloromercuriphenyl sulfonate (PCMPS) was added to the plasma to a final concentration of 0.002 M to facilitate comparison with other experiments with normal plasma, in which PCMPS was always added to inhibit LCAT activity. de- scribed previously (8) except that the patients' VLDL and LDL were removed by ultracentrifugal flotation at a density of 1.063 g/ml rather than by chromatography on hydroxylapatite. 20-ml fractions of the effluent were collected. In the experiments in which subfractions from the Sephadex columns were rechromatographed or incubated with LCAT, etc., the proteins were concentrated by ultrafiltration through Diaflo filters (Amicon Corp., Lexington, Mass.). LCAT was prepared from normal plasma as described previously (6) . The preparations were usually 40-to 150-fold purified. In all incubation experiments in which the partially purified enzyme was used, the concentration of the enzyme in the incubation medium was adjusted to approximately that of native plasma. This adjustment was based on assays (9) of the activity of the partially purified enzyme and of the freshly obtained plasma used as starting material in preparing the enzyme. These assays, performed 1-2 days before the incubation experiment, were used to calculate the amounts of purified enzyme to be included in the incubation medium. These amounts contained only traces of lipid. In other experiments, advantage was taken of the endogenous LCAT activity present in the d > 1.063 g/ml of proteins of normal plasma. This was done in all cases in which normal HDL were preincubated in the presence of the enzyme and subsequently incubated further with LDL or VLDL. In these experiments d > 1.063 g/ml of proteins were prepared from the plasma by ultracentrifugation, dialyzed against Tris-EDTA-NaClI for at least 18 hr, and incubated for 18 hr at 370C (usually in the presence of 0.01 M mercaptoethanol). Subsequently, the enzyme was inactivated by heating at 56-600C for 30 min or, after removing the mercaptoethanol by dialysis against Tris-EDTA-NaCl, by adding PCMPS to a final concentration of 0.002.M.
Lipid transfer experiments. Unless specifically stated otherwise, lipoproteins from the patients or from normal subjects were incubated for 18 hr at 370C with normal HDL which had either been pretreated with LCAT or had been protected from action of the enzyme in vitro. Control experiments were performed by incubating the lipoproteins separately. After the incubations the lipoproteins were chromatographed in quintuplicate on columns of hydroxylapatite (8) . The HDL were eluted with 0.25 M potassium phosphate, the salt was removed by dialysis against distilled water, the fractions were concentrated against Aquacide (Calbiochem, Los Angeles, Calif.), and lipids were extracted by adding 20 vol of chloroform: methanol (1: 1). Lipids of LDL or VLDL were directly eluted from the column with approximately 15 times the column volume of chloroform: methanol (1:1). Recoveries of total (HDL + LDL or VLDL) lipid varied from 80 to 100%o unless specifically noted in the text. Two types of transfer experiments were performed with the patients' HDL. In one the HDL were incubated with erythrocyte membranes prepared from the blood of normal humans (10) . After incubation the erythrocyte membranes were removed by centrifugation for 15-30 min at 20,000 rpm in a Spinco No. 40 rotor followed by filtration through Millipore filters (Millipore Corporation, Bedford, Mass.). In the second type of transfer experiment, the patients' HDL were incubated with normal HDL, which had been coupled to Sepharose 2B (Pharmacia Fine Chemicals, New Market, N. J.) (11) , and perincubated with LCAT. The coupling procedure routinely yields preparations that contain about the same amount of HDL per gram wet weight of Sepharose as is normally present per milliliter of human plasma. After preincubation with LCAT, the HDLSepharose was washed with Tris-EDTA-NaCl, reacted with 0.1 M N-ethylmaleimide for 20 min at room temperature to inactivate residual LCAT activity, and again washed with Tris-EDTA-NaCl. After incubating the HDL-Sepharose with the patients' HDL, the latter were separated from the coupled HDL by filtration.
Lipid analyses. Measurements of cholesterol and phospholipid were performed as described previously (8) . Tri (14) (15) (16) (17) . They show that the following significant relationships exist: the ratio of cho-10.01 N Tris HCl, 0.001 M EDTA, 0.14 N NaCl, pH 7.4. Redrawn from data published earlier (8) . Experimental and figure details as in part A except that VLDL and LDL were removed by chromatography on hydroxylapatite before gel filtration.
to the LDL, and in the HDL the ratio is less than half of normal. The ratio of lecithin to sphingomyelin appears to decrease from the VLDL to the LDL of densities 1.006-1.019 g/ml, but does not decrease further to the LDL of densities 1.019-1.063 g/ml. As a result the ratio is about three times greater than normal in the lipoproteins of this density, a fact which is consistent with the absence of LCAT, since LCAT decreases lecithin but has no effect on sphingomyelin.
Total concentrations of VLDL cholesterol, lecithin, and triglyceride are increased in the plasma of A. R. and A. A., but not in the plasma of M. R., the youngest patient. The increased concentrations of VLDL in the two older patients seem to be associated with increased concentrations of LDL, although total concentrations of unesterified cholesterol and lecithin in the LDL are increased in all the patients. The concentration of HDL unesterified cholesterol is normal or nearly normal, but the concentrations of HDL lecithin and total cholesterol are less than half of normal.
Further abnormalities of the patients' HDL are illustrated by the experiment shown in Fig. 1 . In this experiment proteins of d > 1.063 g/ml from the plasma of MI. R. were subfractionated by gel filtration on Sephadex G 200. The two lipoprotein subfractions shown in Fig. 1 A (solid curve) emerge in the same positions as those obtained by Torsvik (19) . They correspond approximately to the flanks of the single peak always obtained in comparable experiments with normal plasma (Fig. 1 B, Reactivity of the patients' lipoproteins with LCAT. The patients' lipoproteins appear to react normally with partially purified preparations of LCAT from normal plasma (Table III, Fig. 2 ). The patients' VLDL, like normal VLDL (6), do not react significantly with the enzyme, but the patients' LDL do. Fig. 2 shows that the patients' HDL react with LCAT and suggests that the smaller molecular weight HDL (HDL peak II) il are more reactive than the larger molecular weight HDL (HDL peak I). A similar relation has been observed (8) between the reactivity of smaller and larger molecular weight subfractions of normal HDL. It should be noted that the experiment shown in Fig. 2 was designed to compare the reactivity of the two HDL subfractions on the basis of their initial content of lecithin 2 and that normal erythrocyte membranes were included in the incubation mixture to provide a continuing supply of unesterified cholesterol (20) , but that both the lecithin and the unesterified cholesterol of the HDL subfractions decreased in the presence of these membranes (Table  IV) . This decrease occurred even in the absence of LCAT and also occurred in experiments with HDL from A. R. Since the absolute amounts of lecithin and unesterified cholesterol lost from the HDL peak I subfraction were greater than those lost from the HDL peak II subfraction (Table IV) , the two HDL substrates in the experiment shown in Fig. 2 are not strictly comparable on the basis of lecithin content. Nevertheless, the absolute increase in cholesteryl ester in the HDL peak II subfraction was almost three times greater than that in the HDL peak I subfraction, a relation far out of proportion to the difference in lecithin content between the two subfractions. Hence, the HDL peak II subfraction appears to have been a better substrate. Note that LCAT promoted an increase in the total cholesterol of both subfractions compared to controls incubated with erythrocyte membranes in the absence of the enzyme (Table V) . A nearly 3-fold increase occurred in the case Incubation time (hours) FIGURE 2 Reactivity of HDL subfractions with LCAT. Plasma proteins of d> 1.063 g/ml from M. R. were fractionated by gel filtration as shown in Fig. 1 g/ml from normal plasma in the presence or absence of LCAT activity. VLDL cholesteryl ester (Fig. 3 Fig. 3 (lower part) also shows that the unesterified cholesterol of the VLDL of A. R. decreased and that the change was greater in the presence than in the absence of the enzyme. The changes in VLDL unesterified cholesterol and cholesteryl ester in this experiment probably were indirect effects of the LCAT reaction since LCAT has no effect on the patients' VLDL in the absence of HDL (Table III) and since similar changes occur when VLDL are incubated in the presence of normal HDL that have been preincubated with the enzyme. In the experiment shown in Fig. 5 VLDL unesterified cholesterol decreased and VLDL cholesteryl ester increased significantly even though control values for the total unesterified cholesterol and cholesteryl ester of the mixture (not shown) did not change. Similarly, a significant, although smaller, decrease in VLDL lecithin also occurred in the absence of a change in total (VLDL + HDL) lecithin. However, in this experiment the yields of lecithin from the hydroxylapatite columns were unaccountably low (65%) in both test and control columns. No significant change in VLDL triglyceride 1 design of the experiments shown in these figures was similar to that of the experiment shown in Fig. 5 . Incubation with normal, preincubated HDL increased the LDL cholesteryl ester and decreased the LDL unesterified cholesterol, lecithin, and triglyceride (Fig. 7) . Similar, although less pronounced, transfers occurred when the patients' LDL were incubated with normal nonpreincubated HDL (Fig. 8) . and lecithin decreased but neither the LDL cholesteryl ester nor triglyceride changed. Similar results were obtained in a second experiment. Since the decrease in lecithin in both experiments was considerably less than the decrease in unesterified cholesterol, these results appear to explain why incubation of whole plasma causes a smaller decrement in LDL lecithin than in LDL unesterified cholesterol (23) . While direct action of LCAT causes nearly equimolar changes in lecithin and unesterified cholesterol (24) , nonenzymic transfers of these lipids subsequently occur from LDL to HDL, and these are not equimolar. Fig. 9 B shows an experiment in which the same normal LDL used in the experiment in Fig. 9 A were incubated with HDL which had not previously reacted with LCAT in vitro. No significant changes in LDL unesterified cholesterol, lecithin, cholesteryl ester, or triglyceride occurred. It can be concluded that the patients' LDL are abnormal in that they gain cholesteryl ester and lose triglyceride in the presence of either preincubated or untreated HDL and lose unesterified cholesterol and lecithin in the presence of untreated HDL. Fig. 10 shows that extensive transfer of lipid occurred when the HDL peak I subfraction from the plasma of A. A. was incubated with normal, preincubated HDL. In this experiment the normal HDL were coupled to Sepharose to facilitate separation from the abnormal HDL (see Methods). Incubation with the preincubated HDL-Sepharose markedly decreased the lecithin and unesterified cholesterol and increased the cholesteryl ester of the abnormal lipoproteins. These results suggest that the patients' HDL peak I lipoproteins behave similarly to the patients' VLDL and LDL. However, they must be qualified in view of the evidence (25) Fig. 1 A) appears to correspond to the lower molecular weight HDL subfractions obtained on gel filtration of normal HDL (Fig. 1 B) . The lower molecular weight subfractions from both types of plasma contain relatively large proportions of lecithin and appear to be better substrates of LCAT than higher molecular weight HDL subfractions. These properties of the normal HDL and the fact that the cholesteryl esters of corresponding subfractions from baboon plasma rapidly become labeled after the in vivo injection of radioactive mevalonate formed the basis of a postulate (8) (18) that the reaction regulates the cholesterol content of plasma membranes and serves in the transport of cholesterol from peripheral tissues to the liver. We believe that the concepts are not mutually exclusive and that they should be combined. The fact that net transfers of unesterified cholesterol and lecithin occur from the patients' VLDL and LDL to normal HDL suggests that an excess of these lipids indeed develops in the absence of LCAT. Also, it seems likely that this excess distributes among plasma lipoproteins and plasma membranes and that this accounts for the abnormally large amounts of unesterified cholesterol and lecithin associated with the patients' erythrocytes (4). Our results suggest that LCAT normally reduces this excess through a combination of direct and indirect effects. The enzyme does not react directly with VLDL but is able to decrease indirectly VLDL unesterified cholesterol and lecithin by promoting nonenzymic transfers to HDL. Similarly, LCAT promotes nonenzymic transfer of unesterified cholesterol and to a lesser extent lecithin from LDL to HDL, although it also acts directly on LDL. These indirect effects can be presumed to occur in vivo because LCAT reacts preferentially with HDL (8) and because this preferential action would be expected to have a relative effect on HDL unesterified cholesterol and lecithin analogous to that of the separate HDL-LCAT preincubation step in our in vitro experiments (see Figs. 6 A and 9 A). It is worth noting that because of the nonenzymic transfers much of the HDL unesterified cholesterol that reacts with LCAT is probably derived from VLDL and LDL, whereas much of the cholesteryl ester formed probably transfers to VLDL and may ultimately become the major lipid component of LDL (30) (31) (32) . Seen from a wider perspective, the net effect of the LCAT reaction could be to prevent unesterified cholesterol and lecithin originally derived from VLDL from excessively accumulating in plasma membranes. For reasons outlined previously (18) , it seems also likely that the LCAT reaction indirectly affects cholesterol synthesized or pathologically deposited in peripheral tissues, which introduces the possibility that the transport of cholesterol from peripheral tissues to the liver may compete with the removal of excess VLDL cholesterol, i.e., that the rate of VLDL turnover may affect the rate of removal of tissue cholesterol.
